Matthew D. Vesely

7.9k total citations · 4 hit papers
52 papers, 4.1k citations indexed

About

Matthew D. Vesely is a scholar working on Immunology, Oncology and Rheumatology. According to data from OpenAlex, Matthew D. Vesely has authored 52 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Immunology, 23 papers in Oncology and 14 papers in Rheumatology. Recurrent topics in Matthew D. Vesely's work include Immunotherapy and Immune Responses (16 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Immune Cell Function and Interaction (11 papers). Matthew D. Vesely is often cited by papers focused on Immunotherapy and Immune Responses (16 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Immune Cell Function and Interaction (11 papers). Matthew D. Vesely collaborates with scholars based in United States, Australia and United Kingdom. Matthew D. Vesely's co-authors include Robert D. Schreiber, Mark J. Smyth, Michael H. Kershaw, Lieping Chen, Tianxiang Zhang, J. Michael White, Vincent Magrini, Jasreet Hundal, Lloyd J. Old and Cora D. Arthur and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Matthew D. Vesely

42 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Natural Innate and Adaptive Immunity to Cancer

2011 1.5k citations Matthew D. Vesely, Robert D. Schreiber et al. profile →
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

2012 932 citations Matthew D. Vesely, Mark J. Smyth et al. profile →
Resistance Mechanisms to Anti-PD Cancer Immunotherapy

2022 281 citations Matthew D. Vesely, Lieping Chen et al. profile →
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

2022 180 citations Alexander X. Lozano, Aadel A. Chaudhuri et al. Nature Medicine profile →

Peers

Countries citing papers authored by Matthew D. Vesely

Since Specialization

Citations

This map shows the geographic impact of Matthew D. Vesely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew D. Vesely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew D. Vesely more than expected).

Fields of papers citing papers by Matthew D. Vesely

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew D. Vesely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew D. Vesely. The network helps show where Matthew D. Vesely may publish in the future.

Co-authorship network of co-authors of Matthew D. Vesely

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew D. Vesely. A scholar is included among the top collaborators of Matthew D. Vesely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew D. Vesely. Matthew D. Vesely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PD-1H (VISTA) Expression in Cutaneous Squamous Cell Carcinoma Is Correlated with T-Cell Infiltration and Activation 2025 ·Journal of Investigative Dermatology ·(unknown), Christina Cho, Francesc López‐Giráldez, (unknown), (unknown), Patricia Gaule, Lieping Chen, Matthew D. Vesely	0
2	Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention 2025 ·Journal of Clinical Investigation ·Matthew D. Vesely, Sean R. Christensen	0
3	Immune Checkpoint Agonists for Inflammatory Skin Diseases 2025 ·Journal of Investigative Dermatology ·Matthew D. Vesely, Paul F. Lizzul, Paul Klekotka, Nicole Joller, Adam B. Raff	1
4	Spatial Transcriptomics Reveals Differential Inflammatory Pathways in Discoid Lupus Erythematosus and Lichen Planus 2025 ·Journal of Investigative Dermatology ·(unknown), Christina Cho, Francesc López‐Giráldez, (unknown), (unknown), (unknown), (unknown), William Damsky, Lieping Chen, Matthew D. Vesely	0
5	Intravenous immunoglobulin-induced eczematous dermatitis treated with dupilumab 2024 ·JAAD Case Reports ·(unknown), (unknown), (unknown), William Damsky, Keith A. Choate, Matthew D. Vesely	0
6	Spatial Transcriptomics in Inflammatory Skin Diseases Using GeoMx Digital Spatial Profiling: A Practical Guide for Applications in Dermatology 2024 ·SHILAP Revista de lepidopterología ·Christina Cho, Nazgol‐Sadat Haddadi, (unknown), Gavitt A. Woodard, Saeed Shakiba, (unknown), Jillian M. Richmond, Matthew D. Vesely	1
7	HIF-1 regulates pathogenic cytotoxic T cells in lupus skin disease 2023 ·JCI Insight ·Alicia J. Little, Ping-Min Chen, Matthew D. Vesely, (unknown), (unknown), James Garritano, (unknown), Jennifer M. McNiff, Joe Craft	8
8	Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes 2023 ·Journal of Investigative Dermatology ·Matthew D. Vesely, (unknown), Patricia Gaule, Swati Gupta, (unknown), Xue Han, Jacky T. Yeung, Lieping Chen	5
9	Pembrolizumab-induced lichenoid dermatitis treated with dupilumab 2023 ·JAAD Case Reports ·Jonathan J. Park, (unknown), William Damsky, Matthew D. Vesely	4
10	The CD8α–PILRα interaction maintains CD8 ⁺ T cell quiescence 2022 ·Science ·Linghua Zheng, Xue Han, Sheng Yao, Yuwen Zhu, John D. Klement, Shirley Wu, Lan Ji, Gefeng Zhu, Xiaoxiao Cheng, Zuzana Tobiásová, Weiwei Yu, (unknown), Matthew D. Vesely, Jun Wang, Jianping Zhang, Edward Quinlan, Lieping Chen	15
11	T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma breakdown → 2022 ·Nature Medicine ·Alexander X. Lozano, Aadel A. Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah Earland, Matthew D. Vesely, Abul Usmani, Brandon E. Turner, Chloé B. Steen, Bogdan Luca, Ti Badri, Gunsagar S. Gulati, Milad R. Vahid, (unknown), Peter K. Harris, David Y. Chen, Kavita M. Dhodapkar, Mario Sznol, Ruth Halaban, Aaron M. Newman	180
12	Cancer Immunoediting in the Era of Immuno-oncology 2022 ·Clinical Cancer Research ·Matthew M. Gubin, Matthew D. Vesely	75
13	Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis 2021 ·SHILAP Revista de lepidopterología ·Alice Wang, Alexander L. Fogel, Michael J. Murphy, Gauri Panse, Meaghan K. McGeary, Jennifer M. McNiff, Marcus Bosenberg, Matthew D. Vesely, Jeffrey M. Cohen, Christine J. Ko, Brett King, William Damsky	26
14	Normalization Cancer Immunotherapy for Melanoma 2020 ·Journal of Investigative Dermatology ·Matthew D. Vesely, Lieping Chen	21
15	Onychodystrophy associated with dupilumab therapy for atopic dermatitis 2020 ·JAAD Case Reports ·Amanda Zubek, Matthew D. Vesely	5
16	PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus 2019 ·Science Translational Medicine ·Xue Han, Matthew D. Vesely, Wendy Yang, Miguel F. Sanmamed, Ti Badri, Jude Alawa, Francesc López‐Giráldez, Patricia Gaule, (unknown), Jianping Zhang, Xinxin Nie, Ala F. Nassar, Agedi Boto, Dallas B. Flies, Linghua Zheng, Tae Kon Kim, Gilbert Moeckel, Jennifer M. McNiff, Lieping Chen	101
17	Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib 2019 ·JAAD Case Reports ·William Damsky, Matthew D. Vesely, Alfred Ian Lee, Jaehyuk Choi, (unknown), Michael Chen, Tariq Ahmad, Brett King	27
18	Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis 2016 ·JAAD Case Reports ·Matthew D. Vesely, Suguru Imaeda, Brett King	20
19	Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State 2012 ·Cancer Research ·Michele W.L. Teng, Matthew D. Vesely, Helene Duret, Nicole M. McLaughlin, Jennifer E. Towne, Robert D. Schreiber, Mark J. Smyth	88
20	Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis 2008 ·Proceedings of the National Academy of Sciences ·Jeremy B. Swann, Matthew D. Vesely, Anabel Silva, Janelle Sharkey, Shizuo Akira, Robert D. Schreiber, Mark J. Smyth	244

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact